| Shusmita Dhar, MD | |
|
300 Needham St Ste 1b, Newton, MA 02464-1572 | |
| (617) 903-5000 | |
| Not Available |
| Full Name | Shusmita Dhar |
|---|---|
| Gender | Female |
| Speciality | Pediatric Medicine |
| Experience | 20 Years |
| Location | 300 Needham St Ste 1b, Newton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255467965 | NPI | - | NPPES |
| 110080127A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 233935 (Massachusetts) | Secondary |
| 207R00000X | Internal Medicine | 233935 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mass General Brigham Community Physicians Inc | 1759273436 | 297 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the second quarter ended June 30, 2010. Total net revenue was $38,164,000 compared to $38,879,000 in the prior year second quarter. Same-facility net revenue declined 1% for the quarter. Net income from continuing operations attributable to NovaMed in the second quarter of 2010 was $1,805,000, or $0.23 per diluted share, compared to $2,290,000, or $0.30 per diluted share, in the prior year second quarter.
A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.
America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Scientists looking for new ways to fight tuberculosis have their sights set on a structure essential to the bacterium's survival. Disabling this structure could kill the microbes in the infected host and thwart TB infections. In a study appearing online May 11, 2010, in EMBO J, the journal of the European Molecular Biology Organization, scientists from the U.S. Department of Energy's Brookhaven National Laboratory, Stony Brook University, and Weill Cornell Medical College describe new features of how this structure, known as a proteasome, is put together and how it works.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
› Verified 5 days ago
| Entity Name | Mass General Brigham Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891112637 PECOS PAC ID: 1759273436 Enrollment ID: O20150723007726 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the second quarter ended June 30, 2010. Total net revenue was $38,164,000 compared to $38,879,000 in the prior year second quarter. Same-facility net revenue declined 1% for the quarter. Net income from continuing operations attributable to NovaMed in the second quarter of 2010 was $1,805,000, or $0.23 per diluted share, compared to $2,290,000, or $0.30 per diluted share, in the prior year second quarter.
A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.
America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Scientists looking for new ways to fight tuberculosis have their sights set on a structure essential to the bacterium's survival. Disabling this structure could kill the microbes in the infected host and thwart TB infections. In a study appearing online May 11, 2010, in EMBO J, the journal of the European Molecular Biology Organization, scientists from the U.S. Department of Energy's Brookhaven National Laboratory, Stony Brook University, and Weill Cornell Medical College describe new features of how this structure, known as a proteasome, is put together and how it works.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shusmita Dhar, MD 454 Broadway, Suite 100, Revere, MA 02151-3034 Ph: (781) 485-8222 | Shusmita Dhar, MD 300 Needham St Ste 1b, Newton, MA 02464-1572 Ph: (617) 903-5000 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the second quarter ended June 30, 2010. Total net revenue was $38,164,000 compared to $38,879,000 in the prior year second quarter. Same-facility net revenue declined 1% for the quarter. Net income from continuing operations attributable to NovaMed in the second quarter of 2010 was $1,805,000, or $0.23 per diluted share, compared to $2,290,000, or $0.30 per diluted share, in the prior year second quarter.
A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.
America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Scientists looking for new ways to fight tuberculosis have their sights set on a structure essential to the bacterium's survival. Disabling this structure could kill the microbes in the infected host and thwart TB infections. In a study appearing online May 11, 2010, in EMBO J, the journal of the European Molecular Biology Organization, scientists from the U.S. Department of Energy's Brookhaven National Laboratory, Stony Brook University, and Weill Cornell Medical College describe new features of how this structure, known as a proteasome, is put together and how it works.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
› Verified 5 days ago
John D Freedman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 29 Crafts St, Suite 470, Newton, MA 02458 Phone: 617-243-9509 | |
Ms. Marta Christov, MD, PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St Ste 460, Newton, MA 02462 Phone: 617-243-5420 | |
Caroline Stowell, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Medical Education, Newton, MA 02462 Phone: 617-243-6467 Fax: 617-243-6701 | |
John L Yang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-219-1230 Fax: 617-831-7350 | |
Dr. Harley Anne Simeone, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 272 Centre St, Newton, MA 02458 Phone: 617-796-7170 Fax: 617-796-7171 | |
Meghan E Gange, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6345 | |
Dr. Arthur Robert Kennedy Jr., M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Department Of Hospital Medicine, Newton, MA 02462 Phone: 617-243-6433 |